Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Olomorasib?
Olomorasib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Non-Small Cell...
Olomorasib by Eli Lilly and Co for Non-Small Cell Lung Cancer: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase III for Non-Small Cell Lung Cancer....
Olomorasib by Eli Lilly and Co for Endometrial Cancer: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase II for Endometrial Cancer. According to...
Olomorasib by Eli Lilly and Co for Solid Tumor: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase II for Solid Tumor. According to...
Olomorasib by Eli Lilly and Co for Pancreatic Cancer: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase II for Pancreatic Cancer. According to...
Olomorasib by Eli Lilly and Co for Colorectal Cancer: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase II for Colorectal Cancer. According to...
Olomorasib by Eli Lilly and Co for Ovarian Cancer: Likelihood of Approval
Olomorasib is under clinical development by Eli Lilly and Co and currently in Phase II for Ovarian Cancer. According to...